Dymista® is included in the British Society of Allergy and Clinical Immunology (BSACI) Rhinitis Guidelines as a treatment option for allergic rhinitis patients
BSACI Guideline - Dymista® leads to greater symptom improvement than azelastine or fluticasone propionate (FP) alone1
Click below to learn more about Dymista®'s position in the BSACI Rhinitis Guidelines
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
Impact of Rhinitis
- Scadding GK, et at BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017, First edition 2007). Clin Exp Allergy 2017; 47(7): 856–889.
- Lipworth B, et al. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017; 27(1)